Slide 1: Second Quarter 2023 Earnings Presentation
ANGIODYNAMICS Second Quarter 2023 Earnings Presentation January 5, 2023 1
Slide 2: Forward-Looking Statement
Forward-Looking Statement Notice Regarding Forward-LookingStatements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, ca
Slide 3: Corporate Developments – Q2 and YTD FY23 Highlights
Corporate Developments – Q2 and YTD FY23 Highlights • Continued focused investment in our 3 key Med Tech platforms: Auryon, Thrombus Management & NanoKnife • Q2 revenue growth of 9.1% Ø Med Tech up 29.7%; Med Device up 2.6% Ø $10.1 million in Auryon sales Ø Mechanical Thrombectomy (AngioVac and Alph
Slide 4: Q2 and YTD FY23 Results (unaudited)
Q2 and YTD FY23 Results (unaudited) $ in thousands (except per share data) Q2 FY23 Q2 FY22 Change YTD FY23 YTD FY22 Change Revenue $85,429 $78,280 9.1% $166,966 $155,251 7.5% Med Tech $24,502 $18,886 29.7% $47,318 $36,493 29.7% Med Device $60,927 $59,394 2.6% $119,648 $118,758 0.7% United States $71
Slide 5: Q2 and YTD FY23 Highlights
Q2 and YTD FY23 Highlights Q2 Revenue Contribution YTD Revenue Contribution Med Tech Med Tech Med Device Med Device Q2 FY22 Q2 FY23 YTD FY22 YTD FY23 24% 29% 24% 28% 76% 71% 76% 72% Q2 Revenue Growth YTD Revenue Growth Q2 FY22 Q2 FY23 YTD FY22 YTD FY23 24.5 36.5 47.3 18.9 29.7% growth 29.7% growth 5
Slide 6: Sales Comparison to Prior-Year Periods
Sales Comparison to Prior-Year Periods Med Tech Q2 FY23 YTD FY23 Auryon 60.6% 55.5% Thrombus Management* (0.3%) 14.5% AngioVac (16.2%) (4.6%) AlphaVac** 205.3% N/A NanoKnife® Disposables 45.4% 28.9% NanoKnife® Capital 64.1% 1.5% Med Device Q2 FY23 YTD FY23 Solero® Microwave 7.0% 6.6% BioSentry (8.8%
Slide 7: FY23 Guidance Reaffirmed
FY23 Guidance FY23 Guidance Reaffirmed Revenue $342 - $348 million Gross Margin 52.5% - 54.5% Med Tech 65% - 68% Med Device 45% - 48% Adjusted EPS $0.01 - $0.06 7
Slide 8: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation 8
Slide 9: Reconciliation of GAAP to Non-GAAP Net Income
Reconciliation of GAAP to Non-GAAP Reconciliation of Net Loss to Adjusted Net Income (Loss) and EPS EBITDA (in thousands, except per share data) (in thousands) (1) Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write-of